PURPOSE: To assess renal cell carcinoma (RCC) stage migration in a large European academic centre series over 25 years and its possible impact on patients' metastasis-free survival. METHODS: The pathology reports of 2,333 consecutive patients with RCC who underwent nephrectomy from 1984 to 2006 at our institution were systematically re-evaluated. Patients were pooled into four groups according to the date of surgery: group 1: 1984-1989, group 2: 1990-1995, group 3: 1996-2001 and group 4: 2002-2006, respectively. Changes in pT-categories over time and the impact on 5- and 10-year metastasis-free survival were evaluated. RESULTS: Organ-confined (pT1 and pT2) tumours were found in 191/502 (38.0 %) and 372/535 (69.5 %) surgical specimens in groups 1 and 4, respectively (p < 0.001). This stage migration was mainly the result of an increase in pT1a tumours (overall: 32.6 %) from 12.5 % in group 1 to 45.8 % in group 4 and a decrease in pT3a tumours (overall: 24.1 %) from 46.6 % in group 1 to 11.0 % in group 4 (p < 0.001). The mean tumour size decreased from 6.7 cm in group 1 to 4.8 cm in group 4 (p < 0.001). In 2,152 patients with non-metastatic RCC, median follow-up was 76.2 (interquartile range: 36.2-133.9) months. Five- and 10-year metastasis-free survival probabilities were 78.7 and 71.9 % in group 1, 85.3 and 80.0 % in group 2, and 86.9 and 82.7 % in group 3, respectively. Five-year metastasis-free survival in group 4 was 90.3 % (p < 0.001). CONCLUSION: A statistically significant stage migration towards organ-confined RCC was observed in the cohort studied. This stage migration was accompanied by a significant improvement in metastasis-free survival comparing the period 1984-1989 and following time periods.
PURPOSE: To assess renal cell carcinoma (RCC) stage migration in a large European academic centre series over 25 years and its possible impact on patients' metastasis-free survival. METHODS: The pathology reports of 2,333 consecutive patients with RCC who underwent nephrectomy from 1984 to 2006 at our institution were systematically re-evaluated. Patients were pooled into four groups according to the date of surgery: group 1: 1984-1989, group 2: 1990-1995, group 3: 1996-2001 and group 4: 2002-2006, respectively. Changes in pT-categories over time and the impact on 5- and 10-year metastasis-free survival were evaluated. RESULTS: Organ-confined (pT1 and pT2) tumours were found in 191/502 (38.0 %) and 372/535 (69.5 %) surgical specimens in groups 1 and 4, respectively (p < 0.001). This stage migration was mainly the result of an increase in pT1a tumours (overall: 32.6 %) from 12.5 % in group 1 to 45.8 % in group 4 and a decrease in pT3a tumours (overall: 24.1 %) from 46.6 % in group 1 to 11.0 % in group 4 (p < 0.001). The mean tumour size decreased from 6.7 cm in group 1 to 4.8 cm in group 4 (p < 0.001). In 2,152 patients with non-metastatic RCC, median follow-up was 76.2 (interquartile range: 36.2-133.9) months. Five- and 10-year metastasis-free survival probabilities were 78.7 and 71.9 % in group 1, 85.3 and 80.0 % in group 2, and 86.9 and 82.7 % in group 3, respectively. Five-year metastasis-free survival in group 4 was 90.3 % (p < 0.001). CONCLUSION: A statistically significant stage migration towards organ-confined RCC was observed in the cohort studied. This stage migration was accompanied by a significant improvement in metastasis-free survival comparing the period 1984-1989 and following time periods.
Authors: John M Hollingsworth; David C Miller; Stephanie Daignault; Brent K Hollenbeck Journal: J Natl Cancer Inst Date: 2006-09-20 Impact factor: 13.506
Authors: Maxime Crépel; Claudio Jeldres; Maxine Sun; Giovanni Lughezzani; Hendrik Isbarn; Ahmed Alasker; Umberto Capitanio; Shahrokh F Shariat; Philippe Arjane; Hugues Widmer; Markus Graefen; Francesco Montorsi; Paul Perrotte; Pierre I Karakiewicz Journal: Urology Date: 2010-10 Impact factor: 2.649
Authors: G Kovacs; M Akhtar; B J Beckwith; P Bugert; C S Cooper; B Delahunt; J N Eble; S Fleming; B Ljungberg; L J Medeiros; H Moch; V E Reuter; E Ritz; G Roos; D Schmidt; J R Srigley; S Störkel; E van den Berg; B Zbar Journal: J Pathol Date: 1997-10 Impact factor: 7.996
Authors: Brett S Carver; Angel M Serio; Dean Bajorin; Robert J Motzer; Jason Stasi; George J Bosl; Andrew J Vickers; Joel Sheinfeld Journal: J Clin Oncol Date: 2007-11-12 Impact factor: 44.544
Authors: Paul Russo; Thomas L Jang; Joseph A Pettus; William C Huang; Scott E Eggener; Matthew F O'Brien; Michael E Karellas; Nicholas T Karanikolas; Megan A Kagiwada Journal: Cancer Date: 2008-07-01 Impact factor: 6.860
Authors: Levente Kuthi; Alex Jenei; Adrienn Hajdu; István Németh; Zoltán Varga; Zoltán Bajory; László Pajor; Béla Iványi Journal: Pathol Oncol Res Date: 2016-12-28 Impact factor: 3.201
Authors: Gregory J Nason; Barry B McGuire; Michael E Kelly; Theodore M Murphy; Aisling T Looney; Damien P Byrne; David W Mulvin; David J Galvin; David M Quinlan; Gerald M Lennon Journal: Can Urol Assoc J Date: 2014-03 Impact factor: 1.862
Authors: Michal Fedorko; Michal Stanik; Robert Iliev; Martina Redova-Lojova; Tana Machackova; Marek Svoboda; Dalibor Pacik; Jan Dolezel; Ondrej Slaby Journal: Int J Mol Sci Date: 2015-09-29 Impact factor: 5.923
Authors: Maximilian Seles; Georg C Hutterer; Tobias Kiesslich; Karl Pummer; Ioana Berindan-Neagoe; Samantha Perakis; Daniela Schwarzenbacher; Michael Stotz; Armin Gerger; Martin Pichler Journal: Int J Mol Sci Date: 2016-04-15 Impact factor: 5.923
Authors: Orietta Dalpiaz; Theresa Luef; Maximilian Seles; Michael Stotz; Tatjana Stojakovic; Karl Pummer; Richard Zigeuner; Georg C Hutterer; Martin Pichler Journal: Br J Cancer Date: 2016-12-01 Impact factor: 7.640
Authors: M Pichler; G C Hutterer; C Stoeckigt; T F Chromecki; T Stojakovic; S Golbeck; K Eberhard; A Gerger; S Mannweiler; K Pummer; R Zigeuner Journal: Br J Cancer Date: 2013-02-05 Impact factor: 7.640